Hepatocellular carcinoma (HCC) remains a highly lethal malignancy due to tumor heterogeneity, frequent recurrence, and therapeutic resistance. Despite advances in surgery, locoregional therapies, targeted therapy, and immunotherapy, long-term outcomes remain suboptimal. A critical unmet need is the identification of biologically defined subtypes that integrate metabolic characteristics, regulated cell death resistance, and prognosis. In this context, Mita et al. demonstrate that concurrent resistance to ferroptosis and disulfidptosis characterize an aggressive, hypermetabolic HCC subset characterized by high cystine/glutamate antiporter xCT (SLC7A11) expression and increased glucose uptake on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) 1. Their findings highlight how metabolic adaptation and cell death resistance interact to drive tumor aggressiveness and influence patient outcomes. Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation and represents a promising therapeutic vulnerability in cancer 2. The xCT transporter suppresses ferroptosis by facilitating cystine uptake and glutathione synthesis, thereby maintaining intracellular redox homeostasis 3. In a cohort of 345 patients undergoing hepatic resection for HCC, Mita et al. found that over half of tumors were xCT positive. High xCT expression was associated with larger tumor size, poor differentiation, elevated tumor markers, and microscopic intrahepatic metastasis. Importantly, xCT positivity independently predicted poorer recurrence-free and overall survival 4. Collectively, these findings reinforce growing evidence that ferroptosis resistance promotes aggressive HCC behavior. xCT-high tumors appear better equipped to tolerate oxidative stress, metabolic strain, and therapeutic pressure facilitating tumor progression and recurrence 5. A notable strength of this study is its incorporation of disulfidptosis, a recently characterized form of regulated cell death induced by cystine overload under glucose-deprived conditions 5. In this context, excessive cystine accumulation induces cytoskeletal collapse through aberrant disulfide bond formation unless cells compensate by enhancing glucose metabolism 6. This conceptual framework suggests that tumors with high xCT expression may be particularly susceptible to disulfidptosis unless they upregulate glucose uptake to preserve redox balance. Accordingly, Mita et al. evaluated tumor glucose metabolism using preoperative FDG-PET/computed tomography (FDG-PET/CT) in a subset of 108 patients 4. xCT-positive tumors demonstrated significantly higher FDG uptake, reflecting increased glycolytic activity and metabolic demand 4. These findings support a biological model in which xCT-high tumors adapt to cystine-induced oxidative stress by augmenting glucose metabolism, thereby evading both ferroptosis and disulfidptosis. The study's key contribution is an integrated prognostic model combining xCT expression with maximum standardized uptake value on FDG-PET. Patients were stratified into four biologically distinct subgroups. Those with xCT-positive tumors and high FDG uptake exhibited the poorest long-term outcomes surpassing the prognostic value of either biomarker alone. This subgroup reflects a hypermetabolic, cell death-resistant phenotype with aggressive tumor behavior and reduced survival following hepatic resection. By linking histopathological biomarkers with noninvasive metabolic imaging, this dual-marker approach provides a practical framework for risk stratification and may guide intensified postoperative surveillance or adjuvant therapy selection 7. Transcriptomic analysis of The Cancer Genome Atlas data further supports this model. xCT expression positively correlated with key genes involved in glucose transport, glycolysis, and the pentose phosphate pathway, including glucose transporter 1, hexokinase 2, and glucose-6-phosphate dehydrogenase. These findings place xCT-high tumors within a broader metabolic reprogramming network that enhances glucose flux and redox capacity 8, supporting growth, oxidative stress resistance, and survival under nutrient stress 9. Together, imaging, molecular, and clinical data underscore how metabolic rewiring, revascularization, and cell death evasion cooperatively drive aggressive HCC biology 10. Emerging evidence indicates that xCT activity and tumor glucose consumption influence the immune microenvironment 11. xCT overexpression is linked to reduced CD8+ T-cell and natural killer cell activity and increased programmed death-ligand expression 12. Meanwhile, high glucose uptake may further impair immune cells of key metabolic substrates 13. Accordingly, tumors with high xCT expression and FDG-PET uptake may represent an immune-evasive phenotype characterized by metabolic competition, redox adaptation, and resistance to immune-mediated cytotoxicity 14. This may contribute to poor outcomes and support combining metabolic targeting, ferroptosis induction, and immunotherapy 15. The xCT transporter (SLC7A11) emerges as a promising therapeutic target in HCC, maintaining redox homeostasis via cystine import and glutathione synthesis, thereby conferring resistance to oxidative stress and ferroptosis 16. Inhibiting SLC7A11 may deplete glutathione, increase lipid peroxidation, and restore ferroptotic vulnerability particularly in xCT-high tumors 3. These cancers also display metabolic liability: to avoid disulfidptosis, they rely on glucose metabolism and nicotinamide adenine dinucleotide phosphate production to sustain reducing capacity 17. Targeting glycolysis, glucose uptake, or nicotinamide adenine dinucleotide phosphate-generating pathways could therefore selectively impair xCT-high tumors and enhance ferroptosis-based therapies 18. In this context, FDG-PET may serve as a functional biomarker of metabolic dependency, enabling patient stratification, treatment selection, and response monitoring 19. Collectively, integrating xCT/ferroptosis targeting, metabolic intervention, and FDG-PET–guided strategies offers a rational framework for precision medicine in metabolically active HCC. Several limitations warrant consideration. First, the retrospective, single-center design may limit generalizability underscoring the need for prospective, multicenter validation. Second, although clinical data link xCT signaling to metabolic dependency, mechanistic evidence remains incomplete; experimental studies should clarify the interplay among xCT activity, glucose metabolism, ferroptosis, and disulfidptosis in HCC. Future research should integrate multi-omics—including transcriptomics, metabolomics, and proteomics—and single-cell profiling to define metabolic heterogeneity and distinct vulnerability HCC subtypes. Finally, prospective evaluation of FDG-PET as a dynamic biomarker of therapeutic response may further facilitate real-time monitoring and precision therapy. Mita et al. show that dual resistance to ferroptosis and disulfidptosis marks an aggressive, hypermetabolic HCC subtype. By integrating histopathology, metabolic imaging, and genomics, they provide a practical framework for risk stratification and targeted therapy. These findings link metabolic reprogramming and cell death resistance to HCC progression advancing precision medicine in liver cancer. The authors have nothing to report. The authors have nothing to report. The authors have nothing to report. The authors declare no conflicts of interest. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
Namisaki et al. (Sun,) studied this question.